Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel

PurposeIntegrating genomic sequencing in clinical care requires standardization of variant interpretation practices. The Clinical Genome Resource has established expert panels to adapt the American College of Medical Genetics and Genomics/Association for Molecular Pathology classification framework for specific genes and diseases. The Cardiomyopathy Expert Panel selected MYH7, a key contributor to inherited cardiomyopathies, as a pilot gene to develop a broadly applicable approach.MethodsExpert revisions were tested with 60 variants using a structured double review by pairs of clinical and diagnostic laboratory experts. Final consensus rules were established via iterative discussions.ResultsAdjustments represented disease-/gene-informed specifications (12) or strength adjustments of existing rules (5). Nine rules were deemed not applicable. Key specifications included quantitative frameworks for minor allele frequency thresholds, the use of segregation data, and a semiquantitative approach to counting multiple independent variant occurrences where fully controlled case-control studies are lacking. Initial inter-expert classification concordance was 93%. Internal data from participating diagnostic laboratories changed the classification of 20% of the variants (n = 12), highlighting the critical importance of data sharing.ConclusionThese adapted rules provide increased specificity for use in MYH7-associated disorders in combination with expert review and clinical judgment and serve as a stepping stone for genes and disorders with similar genetic and clinical characteristics.

[1]  Jonathan S. Berg,et al.  Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels , 2019, Genome Medicine.

[2]  G. Jarvik,et al.  Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants. , 2016, American journal of human genetics.

[3]  Hencher Han-Chih Lee,et al.  Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies. , 2019, The Clinical biochemist. Reviews.

[4]  Euan Ashley,et al.  Insights into Human β-Cardiac Myosin Function from Single Molecule and Single Cell Studies , 2009, Journal of cardiovascular translational research.

[5]  R. Nussbaum,et al.  Modeling the ACMG/AMP Variant Classification Guidelines as a Bayesian Classification Framework , 2018, Genetics in Medicine.

[6]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[7]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[8]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[9]  Michael J Ackerman,et al.  Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.

[10]  Jyothsna Giri,et al.  Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare , 2019, Pharmacogenomics and personalized medicine.

[11]  Andrew J. Hill,et al.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, bioRxiv.

[12]  C. Bustamante,et al.  Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation , 2016, Proceedings of the National Academy of Sciences.

[13]  Michael J Ackerman,et al.  Implantable cardioverter-defibrillator explantation for overdiagnosed or overtreated congenital long QT syndrome. , 2016, Heart rhythm.

[14]  Barry J Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[15]  D. MacArthur,et al.  Using high-resolution variant frequencies to empower clinical genome interpretation , 2016, Genetics in Medicine.

[16]  L. Køber,et al.  One third of Danish hypertrophic cardiomyopathy patients have mutations in MYH7 rod region , 2005, European Journal of Human Genetics.

[17]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[18]  Lea M. Starita,et al.  Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework , 2019, Genome Medicine.

[19]  D. G. MacArthur,et al.  Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.

[20]  Vijai Joseph,et al.  Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Byers,et al.  The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories , 2015, Genetics in Medicine.

[22]  D. Hedges,et al.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.

[23]  Sivakumar Gowrisankar,et al.  The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing , 2014, Genetics in Medicine.

[24]  S. Letovsky,et al.  Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification , 2015, Genetics in Medicine.

[25]  Matthew S. Lebo,et al.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.

[26]  J. Towbin,et al.  Left ventricular non-compaction cardiomyopathy , 2015, The Lancet.

[27]  W. McKenna,et al.  Left ventricular noncompaction and cardiomyopathy: cause, contributor, or epiphenomenon? , 2008, Current opinion in cardiology.

[28]  Trevor J Pugh,et al.  A systematic approach to assessing the clinical significance of genetic variants , 2013, Clinical genetics.

[29]  Jonathan R. Weir-McCall,et al.  Left Ventricular Noncompaction Anatomical Phenotype or Distinct Cardiomyopathy ? , 2016 .